Mirion Technologies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MIR research report →
Range $20 – $25
Price Chart
About the company
Mirion Technologies, Inc. , established in 2005 and formerly known as Global Monitoring Systems, Inc. until its name change in January 2006, is based in Atlanta, Georgia.
- CEO
- Thomas D. Logan
- IPO
- 2020
- Employees
- 3,281
- HQ
- Atlanta, GA, US
AI snapshot
Six angles, distilled from the data.
The stock is in a recovery phase after a deep pullback from its 52-week high of 27.49, but it still sits below the 200-day moving average near 17.8. The 50-day average at 16.32 is now below spot, suggesting the intermediate trend has improved, though the longer-term regime remains mixed.
Street sentiment stays constructive: 8 Buy ratings and 1 Hold, with a consensus Buy and an average target of 22.4 versus a recent cluster of 20-25 targets. Recent revisions have leaned lower, but Jefferies still initiated at Buy and the target range remains above the current trading level.
The next print is set up against a mixed but workable history: Mirion has beaten 5 of the last 7 quarters, including two straight beats before the most recent flat result. Analysts still expect EPS to rise to 0.54049 this year from 0.48715 next year, so shareholders should watch for margin discipline and continued revenue conversion.
Activity is mixed but not strongly directional. The only clear discretionary signal is a 20,000-share CFO purchase, offset by an 8,400-share sale from the Chief Accounting Officer; most other entries are awards, gifts, or in-kind items that are less informative about conviction.
Profitability is modest but improving on a growth base: gross margin is 48.2% and revenue grew 24.5% year over year. Cash generation is solid with $143.3 million of operating cash flow and $179.7 million of free cash flow, while leverage remains meaningful at $1.2337 billion of debt against $419.2 million of cash.
Mirion screens as a niche industrial with better growth than many mature machinery peers, but its 2.69% net margin keeps valuation tied to execution. At 36.57 times earnings, the setup asks for continued earnings expansion rather than multiple compression.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.95B
- P/E
- 143.41
- Fwd P/E
- 29.73
- PEG
- 1.43
- P/S
- 3.79
- P/B
- 2.26
- EV/EBITDA
- 21.61
- Div Yield
- 0.00%
- Gross Margin
- 48.07%
- Op Margin
- 5.96%
- Net Margin
- 2.69%
- ROE
- 1.59%
- ROIC
- 1.51%
Latest fiscal year · YoY change
- Revenue
- $925.40M+7.5%
- Gross Profit
- $438.60M+9.2%
- Op Income
- $51.50M
- Net Income
- $28.80M+179.8%
- EPS
- $0.13+172.2%
- OCF Growth
- +44.6%
- FCF Growth
- +112.5%
- 52W High
- $27.49
- 52W Low
- $14.04
- 50D MA
- $16.35
- 200D MA
- $17.75
- Beta
- 1.07
- RSI (14)
- 44
- Avg Volume
- 4.31M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Mirion delivered a strong Q3 with sharp order growth, backlog conversion, and raised full-year guidance, while also signaling heavier AI and cyber investment will temper near-term margin expansion.· October 28, 2026
- Q3 orders surged 62% year over year excluding M&A to $340 million, with total orders up 85% to $386 million including Paragon and Certrec.
- Q3 revenue was $277.8 million, up 24.5%, with organic growth of 6.5% and adjusted EPS of $0.12.
- Backlog reached $1.25 billion, and management says that backlog is converting into near-term revenue, with about $735 million expected to be recognized in Q4 2026 and full-year 2027.
- Full-year 2026 guidance was raised for total revenue, organic growth, and free cash flow, but the adjusted EBITDA margin range was narrowed lower on segment margin pressure.
- Management said the prior 2028 margin target is now too aggressive because of slower-than-expected medical growth, Paragon margin timing, and higher AI/cyber investment needs.
Third-quarter total revenue was $277.8 million, up 24.5% year over year; organic revenue growth was 6.5%; adjusted EBITDA was $64.8 million, up 23.7%; adjusted EBITDA margin was 23.3% versus 23.5% last year; and adjusted EPS was $0.12, flat year over year. Q3 adjusted free cash flow was $47 million, bringing year-to-date adjusted free cash flow to $107 million, or 58% conversion of adjusted EBITDA. For full-year 2026, Mirion raised total revenue growth guidance to 24% to 25% from 22% to 24%, organic revenue growth to 7% to 8% from 5% to 7%, and adjusted free cash flow to $170 million to $185 million from $155 million to $175 million. The company now expects adjusted EBITDA of $285 million to $292 million with margins of approximately 24.7% to 25.2%, and adjusted EPS of $0.50 to $0.54 per share. Management said fourth-quarter consolidated organic revenue growth should be in the mid- to high-teens, with medical mid-single digits plus and nuclear and safety high teens plus.
Tomo Logan struck a very constructive tone, saying the quarter reflected continued positive momentum in Mirion’s markets and strong backlog conversion into revenue. He emphasized that nuclear power tailwinds are showing up more clearly in orders and backlog, and he pointed to three demand waves: catch-up capital spending, life extensions/power uprates, and digital transformation. He also said Mirion is prioritizing AI and cybersecurity investments, and that the company is willing to accept a less aggressive near-term margin target in order to support longer-term growth and shareholder value.
Brian Schopfer highlighted the financial inflection: revenue of $277.8 million, adjusted EBITDA of $64.8 million, adjusted EBITDA margin of 23.3%, and adjusted EPS of $0.12. He said margin expansion in medical was more than offset by nuclear and safety pressure tied to Paragon legacy projects, mix, and some one-time items, while AI-related initiatives already totaled almost $4 million in year-to-date operating expense and had exceeded the original full-year budget. He also noted $56 million of share repurchases in Q3, $107 million of year-to-date adjusted free cash flow, net leverage of 3.1x at quarter end, and an expected year-end leverage level of about 2.6x assuming no fourth-quarter buybacks or M&A. He added that the company raised free cash flow guidance and expects a blended cost of debt of about 2.8% for the full year.
Analysts focused on the nuclear margin outlook, AI spending, Paragon, order conversion, medical growth, leverage, and inflation. Management said nuclear margins should improve as Paragon legacy issues moderate, but that AI/cyber and medical growth assumptions have changed enough that the old 30% margin target is no longer appropriate; Tomo said he still sees a strong opportunity for annual margin expansion of 1 to 2 points. On capital allocation, management said the framework is roughly 20% to organic CapEx and initiatives, 40% to bolt-on M&A, and 40% back to shareholders via buybacks, while also stressing that leverage must end the year with a 2 in front of it. On orders, management said the backlog is converting nearer term than some investors feared, and that the large-opportunity pipeline remains healthy, including EDF-related projects awaiting EU funding approval.
The bull case from this call is that Mirion is seeing broad-based nuclear momentum translate into both orders and backlog conversion, with orders up 62% ex-M&A and backlog at $1.25 billion. Management sounded confident that nuclear power, life extensions, SMRs, and digital upgrades can sustain growth into 2027 and beyond, while free cash flow and leverage are improving.
The main risks raised on the call were margin pressure in nuclear and safety, softer-than-expected medical growth, and the need to spend more on AI and cybersecurity than previously planned. Management also acknowledged that the prior 2028 margin target was too aggressive, Paragon margin accretion will take longer than expected, and some large projects depend on future funding or timing, including EDF-related work awaiting EU approval.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.1%
- Shares Outstanding
- 245.49M
- Float Shares
- 223.54M
of shares held by institutions
378 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 38.44M | ▲ 176.15K |
| Vanguard Group Inc | 30.35M | ▼ 72.00K |
| Vanguard Portfolio Management LLC | 17.93M | ▼ 249.23K |
| T. Rowe Price Investment Management, Inc. | 14.29M | ▼ 339.72K |
| Vanguard Capital Management LLC | 10.59M | ▼ 24.90K |
| Goldman Sachs Group Inc | 10.41M | ▲ 3.06M |
| State Street Corp | 9.89M | ▼ 32.25K |
| Alyeska Investment Group, L.P. | 9.53M | ▲ 6.83M |
| Cooperman Leon G | 8.38M | 0 |
| Geode Capital Management, LLC | 6.09M | ▼ 194.67K |
| Congress Asset Management Co | 6.03M | ▼ 650.91K |
| Dimensional Fund Advisors LP | 5.89M | ▲ 1.03M |
Held by 384 ETFs
Biggest fund positions in MIR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Kingsley Lawrence D | other | 1,333 |
| Sep 30, 26 | Markopoulos Jody | other | 1,333 |
| Sep 2, 26 | Schopfer Brian | buy | 20,000 |
| Jun 30, 26 | Kingsley Lawrence D | other | 1,095 |
| May 13, 26 | Kingsley Lawrence D | other | 7,383 |
| May 13, 26 | Bockhorst Kenneth | other | 7,383 |
| May 13, 26 | CASCELLA ROBERT | other | 7,383 |
| May 13, 26 | Etzel Steven W. | other | 7,383 |
| May 13, 26 | KUO JOHN W | other | 7,383 |
| May 13, 26 | Markopoulos Jody | other | 7,383 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MIR coverage
Recent articles, reports, and earnings notes.
Want a deeper read on MIR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Mirion: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 17
Existing Nuclear Fleet Upgrades Drive Investment Momentum
etftrends.com · Nov 16
Mirion to Present at Baird's 2026 Global Industrial Conference
businesswire.com · Nov 9
Mirion Technologies, Inc. (MIR) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 28
What Mirion Technologies (MIR) Said on Its Q3 Earnings Call
marketbeat.com · Oct 28
Mirion Technologies (MIR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Oct 27
Mirion Technologies, Inc. (MIR) Matches Q3 Earnings Estimates
zacks.com · Oct 27
Mirion Announces Third Quarter 2026 Financial Results
businesswire.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice
